Page 1

only For personal use impedimedⓇ 27 July 2021 ASX ANNOUNCEMENT QUARTERLY ACTIVITIES REPORT Supplemental Information APPENDIX 4C - Quarter Ended 30 June 2021 ( Q4 FY'21 ) Brisbane , Australia - ImpediMed Limited ( ASX.IPD ) , a medical technology company that uses bioimpedance spectroscopy ( BIS ) technology to generate powerful data to maximise patient health , today released its Appendix 4C - Quarterly Cash Flow report for the period ended 30 June 2021 . Revenue Summary : • Record quarter for Total Revenue for Q4 FY'21 of $ 2.6 million , + 117 % on the previous corresponding period ( pcp ) ( Q4 FY'20 : $ 1.2 million ) and + 13 % quarter over quarter . Record quarter for SOZO® Revenue for Q4 FY'21 of $ 2.3 million , + 109 % pcp ( Q4 FY'20 : $ 1.1 million ) and + 10 % quarter over quarter . Record quarter for SOZO SaaS Revenue for Q4 FY'21 of $ 1.9 million , + 111 % pcp and + 6 % quarter over quarter . ○ о SOZO SaaS Revenue of $ 1.2 million from Core Business ' . SOZO SaaS Revenue of $ 0.7 million from Clinical Business " . Cash Flow Summary : Cash on hand as at 30 June 2021 of $ 19.7 million . Cash receipts from customers for the quarter of $ 2.3 million . Net operating cash outflows for the quarter of $ 3.4 million . Net operating cash outflows for Q1 FY'22 are expected to be well under $ 4.0 million , in line with Q4 FY'21 cash flow . The Company would expect to see a significant drop in cash outflows in the back half of the current financial year ( FY'22 ) . Related Parties : During the quarter , the Company issued shares to Directors as equity- based remuneration in lieu of cash , as described in Item 6 of the Appendix 4C . These payments to directors consisted of Non - Executive Director superannuation of $ 3,000 , as well as $ 143,000 in Directors ' fees accrued and unpaid at 30 June 2021 related to equity - based remuneration . Operational Summary and Key SaaS Metrics : • Record quarter for Patient Tests , with over 37,000 recorded in Q4 FY'21 , + 109 % pcp and + 11 % quarter over quarter . Annual Recurring Revenue of $ 8.7 million , + 67 % pcp and + 6 % quarter over quarter . о ARR of $ 6.1 million from Core Business . O ARR of $ 2.6 million from Clinical Business . Contracted Revenue Pipeline iv of $ 14.5 million , + 33 % pcp and flat quarter over quarter . Total Contract Value ( TCV ) of over $ 12.0 million signed in FY'21 . Over 90 % + gross margins on SaaS Revenue . Churn Rate remains low at just 1 % . ○ Renewal Rate of 100 % on contracts up for renewal during the quarter .